South Korea Resumes A/H1N1 Vaccine Talks With GSK, Novartis, Sanofi-Aventis, Baxter, CSL
This article was originally published in PharmAsia News
SEOUL - One month after South Korea's Ministry for Health, Welfare and Family Affairs failed to select a company to provide A/H1N1 vaccines at what it considered a "reasonable price," the ministry reopened talks with Baxter International, GlaxoSmithKline, Novartis, CSL of Australia and Sanofi-Aventis to calm mounting public pressure to secure the vaccines
You may also be interested in...
SEOUL - Alarmed over the deaths of two South Koreans over the weekend infected with the A/H1N1 virus and over the rising number of people who have fallen victim to the pandemic, the government is moving to have the H1N1 test covered by the national health insurance system
SEOUL - South Korean pharmaceutical company Green Cross recently started "test production" of its own A/H1N1 flu vaccine, after receiving a virus strain from the UK's National Institution for Biological Standards and Control and from the Centers for Disease Control and Prevention of the U.S
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).